SuperworthThermo Fisher Scientific TMO
- Market cap
- $249.1B
- PE
- 35.5×
- 10y median 33.0×
- Forward PE
- 25.0×
- 10y median 22.5×
- Price to sales
- 5.3×
- EV/EBIT
- 34.7×
- Revenue, 12 months
- $47.4B
- +8% on a year ago
- Net margin
- 14.9%
- Free cash flow yield
- n/m
- Q3 FY26 missing
Thermo Fisher Scientific trades at 35.5× trailing earnings, pricier than 65% of the last ten years. Revenue was $47.4B over the last twelve months, up 8% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.9B−5% | $10.3B−3% | $10.5B−1% | $10.6B+0% | $11.4B+5% | $10.4B+0% | $10.9B+3% | $11.1B+5% | $12.2B+7% | $11B+6% | $12B+11% | $12.1B+9% | |
| Cost of revenue | $6.5B−5% | $6.1B−7% | $6.2B−4% | $6.3B+0% | $6.6B+1% | $6.1B−0% | $6.4B+4% | $6.5B+4% | $7.2B+10% | $6.6B+7% | $7.1B+10% | $6.9B+6% |
| Gross profit | $4.4B−5% | $4.2B+2% | $4.3B+2% | $4.3B+0% | $4.8B+10% | $4.2B+1% | $4.4B+1% | $4.6B+6% | $5B+4% | $4.4B+5% | $4.9B+11% | n/a |
| R&D | $327M−16% | $331M−4% | $339M−2% | $346M+9% | $374M+14% | $342M+3% | $352M+4% | $346M+0% | $356M−5% | $336M−2% | $364M+3% | n/a |
| SG&A | $2.1B−7% | $2.2B+3% | $2.1B−2% | $2.1B+2% | $2.2B+3% | $2.1B−5% | $2.1B+1% | $2.2B+3% | $2.4B+7% | $2.2B+5% | $2.3B+9% | $1.9B−14% |
| $1.9B−0% | $1.7B+6% | $1.8B+15% | $1.8B−1% | $2B+9% | $1.7B+3% | $1.8B+1% | $1.9B+6% | $2.3B+12% | $1.9B+9% | $2.1B+14% | $2.3B+17% | |
| Interest expense | $390M+45% | $363M+21% | $354M+9% | $356M−1% | $317M−19% | $303M−17% | $404M+14% | $347M−3% | $365M+15% | $354M+17% | $401M−1% | n/a |
| Pre-tax income | $1.7B−2% | $1.6B+17% | $1.8B+23% | $1.7B−1% | $1.9B+12% | $1.6B+2% | $1.7B−3% | $1.8B+5% | $2.2B+11% | $1.7B+7% | $1.9B+13% | $2.1B+14% |
| $133M−23% | $281M+511% | $128M+146% | $99M+87% | $150M+13% | $95M−66% | $92M−28% | $207M+109% | $153M+2% | $70M−26% | $167M+82% | n/a | |
| Net income | $1.6B+3% | $1.3B+3% | $1.5B+14% | $1.6B−5% | $1.8B+12% | $1.5B+14% | $1.6B+5% | $1.6B−1% | $2B+7% | $1.7B+10% | $1.7B+7% | $1.7B+7% |
| $4.20+4% | $3.46+4% | $4.04+15% | $4.25−4% | $4.78+14% | $3.98+15% | $4.28+6% | $4.27+1% | $5.21+9% | $4.43+11% | $4.68+9% | $4.64+9% | |
| 388M−1% | 384M−1% | 383M−1% | 384M−1% | 383M−1% | 379M−1% | 378M−1% | 378M−2% | 377M−2% | 373M−2% | 371M−2% | n/a |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: Q4 FY09 and Q4 FY25: printed in the fourth-quarter results release. 30 periods, Q2 FY14 to Q3 FY21: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY08 to Q4 FY24: quarter's net income to common over its shares, to the cent. Q4 FY09 and Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 16 periods, Q4 FY08 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY09 and Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $12.8B | $12.8B to $12.9B | $7.14 | $7.02 to $7.28 | 14 |
| Q1 FY27 | $11.7B | $11.7B to $11.8B | $6.04 | $5.70 to $6.15 | 9 |
| Q2 FY27 | $12.5B | $12.3B to $12.6B | $6.61 | $6.53 to $6.71 | 5 |
| Q3 FY27 | $12.7B | $12.5B to $12.8B | $7.12 | $7.03 to $7.23 | 3 |
| Q4 FY27 | $13.5B | $13.4B to $13.7B | $7.85 | $7.76 to $7.97 | 3 |
| Q1 FY28 | $12.4B | $12.3B to $12.6B | $6.88 | $6.79 to $6.98 | 4 |
| Q2 FY28 | $13.2B | $13.1B to $13.4B | $7.34 | $7.25 to $7.45 | 7 |
| Q3 FY28 | $13.4B | $13.2B to $13.5B | $7.52 | $7.43 to $7.64 | 4 |
Peers
Companies in Medical - Diagnostics & Research nearest Thermo Fisher Scientific's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific | $249.1B | 35.5× | 33.0× | 25.0× | 5.3× | +8% | 14.9% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| Peer median | $44.1B | 37.6× | 34.2× | 27.8× | 6.6× | +8% | 15.9% |
Investors who own it
Investors we follow who held Thermo Fisher Scientific at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors2.8% of portfolioadded
- Dan SundheimD1 Capital Partners1.2% of portfolioadded
- Baillie GiffordBaillie Gifford0.3% of portfoliotrimmed
- Tom GaynerMarkel Group0.3% of portfolioadded
- Stanley DruckenmillerDuquesne Family Office0.2% of portfolionew
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Thermo Fisher Scientific
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 39Diagnostics and research stocks with the highest profit margins
- #8of 20Diagnostics and research stocks with the lowest PE ratio
- #8of 15Diagnostics and research stocks cheapest against their own PE history
- #10of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .